Synergistic inhibition of MEK/ERK and BRAF V600E with PD98059 and PLX4032 induces sodium/iodide symporter (NIS) expression and radioiodine uptake in BRAF mutated papillary thyroid cancer cells
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-6614
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Synergistic inhibition of MEK/ERK and BRAF V600E with PD98059 and PLX4032 induces sodium/iodide symporter (NIS) expression and radioiodine uptake in BRAF mutated papillary thyroid cancer cells ; volume:11 ; number:1 ; day:11 ; month:10 ; year:2018 ; pages:1-6 ; date:12.2018
Thyroid research ; 11, Heft 1 (11.10.2018), 1-6, 12.2018
- Urheber
-
Zhang, Honglai
- Beteiligte Personen und Organisationen
-
Chen, Dong
SpringerLink (Online service)
- DOI
-
10.1186/s13044-018-0057-6
- URN
-
urn:nbn:de:101:1-2018111919143942058732
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 14.08.2025, 10:45 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Zhang, Honglai
- Chen, Dong
- SpringerLink (Online service)
Ähnliche Objekte (12)
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation
TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF V600E /TERT promoter double-mutated glioma
BRAF V600E-Mutant Glioblastoma with Extracranial Metastases Responsive to Combined BRAF and MEK Targeted Inhibition: A Case Report
BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature
BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer
Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy
Validierung eines Protokolls zur manuellen, mutationsspezifischen BRAF V600E Immunhistochemie
Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF V600E metastatic colorectal cancer
Drug-induced colitis on BRAF and MEK inhibitors for BRAF V600E-mutated non-small cell lung cancer: a case report
Loss of Phd2 cooperates with BRAF V600E to drive melanomagenesis
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation
TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF V600E /TERT promoter double-mutated glioma
BRAF V600E-Mutant Glioblastoma with Extracranial Metastases Responsive to Combined BRAF and MEK Targeted Inhibition: A Case Report
BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature
BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer
Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy
Validierung eines Protokolls zur manuellen, mutationsspezifischen BRAF V600E Immunhistochemie
Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF V600E metastatic colorectal cancer
Drug-induced colitis on BRAF and MEK inhibitors for BRAF V600E-mutated non-small cell lung cancer: a case report
Loss of Phd2 cooperates with BRAF V600E to drive melanomagenesis
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation
TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF V600E /TERT promoter double-mutated glioma
BRAF V600E-Mutant Glioblastoma with Extracranial Metastases Responsive to Combined BRAF and MEK Targeted Inhibition: A Case Report
BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature
BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer
Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy
Validierung eines Protokolls zur manuellen, mutationsspezifischen BRAF V600E Immunhistochemie
Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF V600E metastatic colorectal cancer
Drug-induced colitis on BRAF and MEK inhibitors for BRAF V600E-mutated non-small cell lung cancer: a case report